TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval

TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.

‘We’re failing right now’ in type 2 diabetes, FDA chief says

ORLANDO — The United States is at a critical juncture in its efforts to treat chronic diseases, particularly type 2 diabetes, and now has a

June 21, 2024

Interim ALIGN Data: Atrasentan Cuts Proteinuria in IgA Nephropathy

SAN DIEGO — A novel drug significantly reduced IgA nephropathy-related proteinuria, according to interim findings of the ALIGN study. In the phase III trial, among

October 28, 2024

aap informs about the actual status of the mandatory convertible bond 2023-2028 – Biotech Investments

EQS-News: aap Implantate AG / Key word(s): Bond aap informs about the actual status of the mandatory convertible bond 2023-2028 06.11.2024 / 23:39 CET/CEST The

November 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.